Table 1 Clinical trials, participants, and vaccines.

From: Pandemic influenza virus vaccines boost hemagglutinin stalk-specific antibody responses in primed adult and pediatric cohorts

Trial

Trial group

N

Vaccination schedule

Immune response sampling schedule

Homologous prime-boost studies in adults

    

Trial 1: A/H1N125

A/H1N1 AS03

29

A/California/07/2009 3.75 µg + AS03A on D0 and D21

Seasonal IIV3 on D42

D0, D21, D42, D182

A/H1N1 non-adjuvanted

29

A/California/07/2009 15 µg on D0 and D21

Seasonal IIV3 on D42

Trial 2: A/H5N126

A/H5N1 AS03

29

A/Indonesia/5/2005 3.75 µg + AS03A on D0 and D21

D0, D21, D42, D182, D385

A/H5N1 non-adjuvanted

27

A/Indonesia/5/2005 15 µg on D0 and D21

Trial 3: A/H9N227

A/H9N2 AS03

30

A/chicken/Hong Kong/G9/1997 3.75 µg + AS03A on D0 and D21

D0, D21, D42, D182

A/H9N2 non-adjuvanted

30

A/chicken/Hong Kong/G9/1997 15 µg on D0 and D21

Seasonal IIV4 study in adults

    

Trial 4: IIV428

IIV4 non-adjuvanted

30

Seasonal IIV4 15 µg per strain at D0

A/Christchurch/16/2010 (H1N1 pdm09)

A/Texas/50/2012 (H3N2)

B/Massachusetts/02/2012 (B Yamagata)

B/Brisbane/60/2008 (B Victoria)

D0, D21

Heterologous prime-boost studies in adults

    

Trial 5: A/H5N1 booster29

A/H5N1 AS03

Indonesia > Turkey

26

A/Indonesia/5/05 3.75 µg + AS03A on D0

Placebo on D182

A/turkey/Turkey/1/2005 3.75 µg + AS03A on D549

D0, D42, D182, D224, D549, D591, D729

A/H5N1 AS03

Turkey > Turkey

29

Placebo on D0

A/turkey/Turkey/1/2005 3.75 µg + AS03A on D182 and D549

Trial 6: A/H5N1 booster30,31

A/H5N1 AS03

Vietnam > Vietnam

53

A/Vietnam/1194/2004 3.75 µg + AS03A on D0 and D365

D0, D21, D182, D365, D385, D549

 

A/H5N1 AS03

Vietnam > Indonesia

49

A/Vietnam/1194/2004 + AS03A on D0

A/Indonesia/5/05 3.75 µg + AS03A on D365

Homologous prime-boost study in children

    

Trial 7: A/H5N132

A/H5N1 AS03

33

A/Indonesia/5/2005 1.90 µg + AS03B at D0 and D21

D0, D21, D42, D385

Placebo

20

Placebo at D0 and D21

  1. aTrials 1, 2 and 3: serum samples from participants who received adjuvanted vaccine were randomly selected, and samples matched by age and study center were then selected from the non-adjuvanted group
  2. bTrial 4: serum samples from participants 18−39 years of age were randomly selected
  3. cTrials 5 and 6: all evaluable samples from eligible participants were used (i.e. no random selection)
  4. dTrial 7: only samples from children (6−35 months) who were seronegative for A/H1N1pdm09 (A/California/07/2009-like) antibodies were selected to ensure that the children had not been primed through prior exposure to A/H1N1 virus. Not all study groups in the original trials were included; only the vaccines that were administered to participants whose samples were used in the present study are shown. IIV3: trivalent inactivated influenza vaccine; IIV4: quadrivalent inactivated influenza vaccine
Back to article page